Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study
Christine E. Jo, Jorge R. Georgakopoulos, Matthew Ladda, Arvin Ighani, Asfandyar Mufti, Aaron M. Drucker, Vincent Piguet, Jensen Yeung
Topics & Concepts
MedicineDupilumabAtopic dermatitisEczema Area and Severity IndexDiscontinuationRetrospective cohort studyDermatologyRandomized controlled trialClinical endpointInternal medicineDermatology and Skin DiseasesAllergic Rhinitis and SensitizationAsthma and respiratory diseases